المؤلفون: Martinez-Lopez, Joaquin, Alonso, Rafael, Wong, Sandy W, Rios, Rafael, Shah, Nina, Ruiz-Heredia, Yanira, Sanchez-Pina, Jose Maria, Sanchez, Ricardo, Bahri, Natasha, Zamanillo, Irene, Poza, Maria, Buenache, Natalia, Encinas, Cristina, Juarez, Luis, Miras, Fatima, Collado, Luis, Barrio, Santiago, Martin, Thomas, Cedena, Maria Teresa, Wolf, Jeffrey

المصدر: Journal of Hematology & Oncology. 14(1)

مصطلحات موضوعية: Rare Diseases, Clinical Research, Hematology, Cancer, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Clinical Decision-Making, Disease Management, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm, Residual, Prognosis, Retrospective Studies, Treatment Outcome, Measurable residual disease, Multiple myeloma, Minimal residual disease, Cardiorespiratory Medicine and Haematology, Oncology and Carcinogenesis

الوصف: The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of MRD results to make clinical decisions in MM has been underexplored to date. In this retrospective study, we present the results from a multinational and multicenter series of 400 patients with MRD monitoring during front-line therapy with the aim of exploring how clinical decisions made based on those MRD results affected outcomes. As expected, achievement of MRD negativity at any point was associated with improved PFS versus persistent MRD positivity (median PFS 104 vs. 45 months, p

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/4c05b133Test

المؤلفون: Encinas, Cristina, Hernández Rivas, José Ángel, Oriol, Albert, Rosiñol, Laura, Blanchard, María Jesús, Bellon, José María, Garcia Sanz, Ramón, Rubia, Javier de la, López Guía, Ana de la, Jiménez Ubieto, Ana, Jarque, Isidro, Iñigo, Belén, Dourdil, Victoria, Arriba, Felipe de, Cuéllar Pérez-Ávila, Clara, González, Yolanda, Hernández, Miguel Teodoro, Bargay, Joan, Granell, Miguel, Rodríguez Otero, Paula, Silvent, Maialen, Cabrera, Carmen, Rios, Rafael, Alegre, Adrián, Gironella, M., González, M. S., Sureda, A., Sampol, A., Ocio, E. M., Krsnik, I., Garcia, A., García Mateo, A., Soler, J. A., Martin, J., Arguiñano, J. M., Mateos, M. V., Blade, J., San Miguel, J. F., Lahuerta, J. J., Martinez Lopez, Joaquin, GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group

المصدر: Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

مصطلحات موضوعية: Mieloma múltiple, Antibiòtics, Multiple myeloma, Antibiotics

وصف الملف: 8 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1038/s41408-022-00652-2Test; Blood Cancer Journal, 2022, vol. 12, num. 4, p. 68; https://doi.org/10.1038/s41408-022-00652-2Test; http://hdl.handle.net/2445/207647Test; 9308998

الإتاحة: https://doi.org/10.1038/s41408-022-00652-2Test
http://hdl.handle.net/2445/207647Test

المؤلفون: Sáenz Madrazo, Nerea, Baeza, Azucena, Encinas, Cristina

المصدر: Revista Sociedade Portuguesa de Oftalmologia; Vol. 47 No. 2 (2023); 139-140 ; Revista Sociedade Portuguesa de Oftalmologia; Vol. 47 N.º 2 (2023); 139-140 ; 1646-6950

مصطلحات موضوعية: Corneal Diseases/ chemically induced, Antibodies, Monoclonal, Humanized/adverse effects, Anticorpos Monoclonais Humanizados/efeitos adversos, Doenças da Cornea/induzida quimicamente

وصف الملف: application/pdf

العلاقة: https://revistas.rcaap.pt/oftalmologia/article/view/27237/22311Test; https://revistas.rcaap.pt/oftalmologia/article/view/27237Test

الإتاحة: https://revistas.rcaap.pt/oftalmologia/article/view/27237Test

المؤلفون: Wong, Sandy W., Bar, Noffar, Victoria Mateos, María, Ribas, Paz, Hansson, Markus, Paris, Laura, Hofmeister, Craig, Rodriguez-Otero, Paula, Aranzazu Bermúdez, Maria, Santoro, Armando, Yee, Andrew J., Creignou, Maria, Encinas, Cristina, Cerchione, Claudio, de la Rubia, Javier, Oriol, Albert, Ferstl, Barbara, Besemer, Britta, Chen, Jinjie, Chung, Alexander, Boss, Isaac W., Gaudy, Allison, LI, Shaoyi, Hsu, Kevin, Godwin, Colin, Burgess, Michael R., San-Miguel, Jesús, Jose Costa, Luciano

المصدر: HemaSphere ; volume 7, issue S3, page e1220745 ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000970436.12207.45Test

المؤلفون: Moreau, Philippe, Chari, Ajai, Oriol, Albert, Martinez-Lopez, Joaquin, Haenel, Mathias, Touzeau, Cyrille, Ailawadhi, Sikander, Besemer, Britta, de la Rubia Comos, Javier, Encinas, Cristina, Mateos, Maria-Victoria, Salwender, Hans, Rodriguez-Otero, Paula, Hulin, Cyrille, Karlin, Lionel, Sureda Balari, Anna, Bargay, Joan, Benboubker, Lotfi, Rosiñol, Laura, Tarantolo, Stefano, Terebelo, Howard, Yang, Shiyi, Wang, Jianping, Nnane, Ivo, Qi, Ming, Kosh, Michele, Delioukina, Maria, Goldschmidt, Hartmut

المساهمون: Janssen Research and Development

المصدر: Blood Cancer Journal ; volume 13, issue 1 ; ISSN 2044-5385

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1038/s41408-023-00805-xTest
https://www.nature.com/articles/s41408-023-00805-x.pdfTest
https://www.nature.com/articles/s41408-023-00805-xTest

المؤلفون: de la Rubia, Javier, González, Bernardo, Cruz-Jentoft, Alfonso J., Iglesias, Lorena, Jarque, Isidro, Persona, Ernesto Pérez, Lluch, Rafael, Marrero, Carmen, Zudaire, Maite, Gironella, Mercedes, Hernández-Rivas, José Ángel, Arnan, Montserrat, Olivier, Carmen, Encinas, Cristina, Soler, Juan Alfonso, Payer, Ángel Ramírez, Casado, Alfonso, Fernández, Patricia, Vilanova, David, Bonanad, Santiago

المصدر: Journal of Geriatric Oncology ; volume 14, issue 1, page 101401 ; ISSN 1879-4068

مصطلحات موضوعية: Geriatrics and Gerontology, Oncology

الإتاحة: https://doi.org/10.1016/j.jgo.2022.10.016Test
https://api.elsevier.com/content/article/PII:S1879406822005203?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1879406822005203?httpAccept=text/plainTest

المؤلفون: Ríos-Tamayo, Rafael, Lecumberri, Ramón, Cibeira, María Teresa, González-Calle, Verónica, Alonso, Rafael, Domingo-González, Amalia, Landete, Elena, Encinas, Cristina, Iñigo, Belén, Blanchard, María-Jesús, Alejo, Elena, Krsnik, Isabel, Gómez-Bueno, Manuel, Garcia-Pavia, Pablo, Segovia-Cubero, Javier, Rosiñol, Laura, Lahuerta, Juan-José, Martínez-López, Joaquín, Bladé, Joan

المصدر: Cancers; May2024, Vol. 16 Issue 9, p1689, 13p

مصطلحات موضوعية: AMYLOIDOSIS diagnosis, STATISTICAL models, FRAIL elderly, AMYLOIDOSIS, AGE distribution, PEPTIDE hormones, MULTIVARIATE analysis, DECISION making in clinical medicine, OVERALL survival, COMORBIDITY, PATIENT aftercare

مستخلص: Simple Summary: Despite a lack of standardization and some open questions, a growing body of evidence supports the use of frailty to optimize the clinical management of patients with hematological malignancies. Several scores have been applied particularly to multiple myeloma, an entity that shares many characteristics with AL amyloidosis, both being frequently associated. To date, no study has focused on frailty in patients with AL amyloidosis. We aimed to define a practical evaluation of frailty and estimate its impact in survival in patients with systemic AL amyloidosis. Systemic AL amyloidosis is a challenging disease for which many patients are considered frail in daily clinical practice. However, no study has so far addressed frailty and its impact on the outcome of these patients. We built a simple score to predict mortality based on three frailty-associated variables: age, ECOG performance status (<2 vs. ≥2) and NT-proBNP (<8500 vs. ≥8500 ng/L). Four-hundred and sixteen consecutive newly diagnosed patients diagnosed at ten sites from the Spanish Myeloma Group were eligible for the study. The score was developed in a derivation cohort from a referral center, and it was externally validated in a multicenter cohort. Multivariate analysis showed that the three variables were independent predictors of survival. The score was able to discriminate four groups of patients in terms of overall survival and early mortality in both cohorts. Comorbidity was also analyzed with the Charlson comorbidity index, but it did not reach statistical significance in the model. A nomogram was created to easily estimate the mortality risk of each patient at each time point. This score is a simple, robust, and efficient approach to dynamically assess frailty-dependent mortality both at diagnosis and throughout follow-up. The optimal treatment for frail AL amyloidosis patients remains to be determined but we suggest that the estimation of frailty-associated risk could complement current staging systems, adding value in clinical decision-making in this complex scenario. [ABSTRACT FROM AUTHOR]

: Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Lakhwani, Sunil, Rosiñol, Laura, Puig, Noemí, Pico-Picos, Miguel-Angel, Medina-González, Laura, Martínez-López, Joaquín, Paiva, Bruno, Cedena, María-Teresa, Oriol, Albert, Ríos-Tamayo, Rafael, Blanchard, María-Jesús, Jarque, Isidro, Bargay, Joan, Moraleda, José-María, Carrillo-Cruz, Estrella, Sureda, Anna, Krsnik, Isabel, González, Esther, Casado, Luis Felipe, Martí, Josep M, Encinas, Cristina, De Arriba, Felipe, Palomera, Luis, Sampol, Antonia, González-Montes, Yolanda, Motlló, Cristina, De La Cruz, Javier, Alonso, Rafael, Mateos, María-Victoria, Bladé, Joan, Lahuerta, Juan-José, San-Miguel, Jesús, Hernández, Miguel-Teodoro

المصدر: Haematologica ; ISSN:1592-8721 ; Volume:109 ; Issue:6

الوصف: Immunoparesis (IP) in multiple myeloma (MM) patients can be measured by classic assessment of immunoglobulin (Ig) levels or by analysis of the uninvolved heavy/light chain pair of the same immunoglobulin (uHLC) by the Hevylite® assay. In this study we evaluate the prognostic value of recovery from IP measured by classic total Ig and uHLC assessment in newly diagnosed MM transplant-eligible (NDMM-TE) patients with intensive treatment and its association with minimal residual disease (MRD). Patients were enrolled and treated in the PETHEMA/GEM2012MENOS65 trial and continued in the PETHEMA /GEM2014MAIN trial. Total Ig (IgG, IgA and IgM) and uHLC were analyzed in a central laboratory at diagnosis, after consolidation treatment and after the first year of maintenance. MRD was analyzed by next-generation flow cytometry after consolidation (sensitivity level 2x10-6). We found no differences in progression-free survival (PFS) between patients who recovered and patients who didn't recover from IP after consolidation when examining classic total Ig and uHLC. However, after the first year of maintenance, in contrast to patients with classic IP, patients with recovery from uHLC IP had longer PFS than patients without recovery, with hazard ratio of 0.42 (95% confidence interval [CI]: 0.21-0.81; P=0.008). Multivariate analysis with Cox proportional-hazards regression models confirmed recovery from uHLC IP after the first year of maintenance as an independent prognostic factor for PFS, with an increase in C-statistic of 0.05 (95% CI: -0.04 to 0.14; P<0.001) when adding uHLC IP recovery. Moreover, we observed that MRD status and uHLC IP recovery affords complementary information for risk stratification. In conclusion, recovery from uHLC IP after 1 year of maintenance is an independent prognostic factor for PFS in NDMM-TE patients who receive intensive treatment. Immune reconstitution, measured as recovery from uHLC IP, provides complementary prognostic information to MRD assessment (clinicaltrials gov. Identifiers: NCT01916252 and NCT02406144).

العلاقة: https://doi.org/10.3324/haematol.2023.284154Test; https://pubmed.ncbi.nlm.nih.gov/38031761Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141681Test/

الإتاحة: https://doi.org/10.3324/haematol.2023.284154Test
https://pubmed.ncbi.nlm.nih.gov/38031761Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141681Test/

المؤلفون: Rosiñol, Laura, Oriol, Albert, Rios, Rafael, Blanchard, Maria Jesús, Jarque, Isidro, Bargay, Juan, Hernández, Miguel Teodoro, Cabanas, Valentín, Carrillo Cruz, Estrella, Sureda, Anna, Martínez López, Joaquín, Krsnik, Isabel, González, María Esther, Casado, Luís Felipe, Martí, Josep Maria, Encinas, Cristina, Arriba, Felipe de, Palomera, Luis, Sampol, Antonia, Gonzalez Montes, Yolanda, Cabezudo, Elena, Paiva, Bruno, Puig, Noemí, Cedena, Maria Teresa, Cruz, Javier de la, Mateos, María Victoria, San Miguel, Jesús, Lahuerta, Juan José, Bladé, J. (Joan)

المصدر: Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

مصطلحات موضوعية: Mieloma múltiple, Quimioteràpia, Multiple myeloma, Chemotherapy

الوصف: From November 2014 to May 2017, 332 patients homogeneously treated with bortezomib, lenalidomide, and dexamethasone (VRD) induction, autologous stem cell transplant, and VRD consolidation were randomly assigned to receive maintenance therapy with lenalidomide and dexamethasone (RD; 161 patients) vs RD plus ixazomib (IRD; 171 patients). RD consisted of lenalidomide 15 mg/d from days 1 to 21 plus dexamethasone 20 mg/d on days 1 to 4 and 9 to 12 at 4-week intervals, whereas in the IRD arm, oral ixazomib at a dose of 4 mg on days 1, 8, and 15 was added. Therapy for patients with negative measurable residual disease (MRD) after 24 cycles was discontinued, whereas those who tested positive for MRD remained on maintenance with RD for 36 more cycles. After a median follow-up of 69 months from the initiation of maintenance, the progression-free survival (PFS) was similar in both arms, with a 6-year PFS rate of 61.3% and 55.6% for RD and IRD, respectively (hazard ratio, 1.136; 95% confidence interval, 0.809-1.603). After 2 years of maintenance, treatment was discontinued in 163 patients with negative MRD, whereas 63 patients with positive MRD continued with RD therapy. Maintenance discontinuation in patients tested negative for MRD resulted in a low progression rate (17.2% at 4 years), even in patients with high-risk features. In summary, our results show the efficacy of RD maintenance and support the safety of maintenance therapy discontinuation in patients with negative MRD at 2 years. This trial was registered at www.clinicaltrials.gov as #NCT02406144 and at EudraCT as 2014-00055410.

وصف الملف: 22 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1182/blood.2022019531Test; Blood, 2023, vol. 142, num. 18, p. 1518-1528; https://doi.org/10.1182/blood.2022019531Test; http://hdl.handle.net/2445/207533Test; 9379843

الإتاحة: https://doi.org/10.1182/blood.2022019531Test
http://hdl.handle.net/2445/207533Test

المؤلفون: Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, Windsor, Kevin

المساهمون: Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesú, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Lui, Kühr, Thoma, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, Jame, Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, Andrá, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35550060; info:eu-repo/semantics/altIdentifier/wos/WOS:000876360100014; volume:9; issue:6; firstpage:e403; lastpage:e414; numberofpages:12; journal:THE LANCET. HAEMATOLOGY; https://hdl.handle.net/2318/1862742Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85131270904; https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026Test(22)00103-X/fulltext; https://doi.org/10.1016/s2352-3026Test(22)00103-x

الإتاحة: https://doi.org/10.1016/S2352-3026Test(22)00103-X
https://doi.org/10.1016/s2352-3026Test(22)00103-x
https://hdl.handle.net/2318/1862742Test
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026Test(22)00103-X/fulltext